Results from the Phase I Pharmacokinetics Study will be cross-referenced, works as an FDA "master file", for all future JOTROL™ indications enabling direct to Phase II trials. Phase I results to be available by end of Q1,2021.
Results from the Phase I Pharmacokinetics Study will be cross-referenced, works as an FDA "master file", for all future JOTROL™ indications enabling direct to Phase II trials. Phase I results to be available by end of Q1,2021.